Salamanca woman jailed on murder, other charges
Breaking News
Salamanca woman jailed on murder, other charges
November 1, 2025
SALAMANCA — A city woman is facing murder and other felony charges after a death on River Street on Friday morning. The Salamanca Police Department re...
Home Online Features Lilly's mirikizumab is first and only IL23p19 antagonist to report long-term, multi-year, sustained efficacy and safety data for both ulcerative colitis and Crohn's disease
Lilly’s mirikizumab is first and only IL23p19 antagonist to report long-term, multi-year, sustained efficacy and safety data for both ulcerative colitis and Crohn’s disease
HO
Press Releases
Eli Lilly and Company  
October 28, 2024

Lilly’s mirikizumab is first and only IL23p19 antagonist to report long-term, multi-year, sustained efficacy and safety data for both ulcerative colitis and Crohn’s disease

At three years, over 80% of patients with moderately to severely active UC who were in remission with mirikizumab sustained long-term remission and relief from disruptive symptoms, including bowel urgency

logo salamanca press

Salamanca Press

email salamanca press
Local & Social